Patent · US Active

Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors

US8957090B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

UCB PHARMA S.A. · BE

Inventors

Gilles Raphy · Saffron Walden, GB
Roland Burli · Pasadena, US
Alan Findlay Haughan · Cambridge, GB

Key dates

Filing date	Nov 11, 2010
Grant date	Feb 17, 2015
Priority date	—
Expiry date	Oct 25, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A series of fused bicyclic pyridine and pyrazine derivatives, substituted directly on the pyridine or pyrazine ring by a functional group attached via a sulphur-containing linkage, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.